58237-09-5

Basic information

• Product Name: KWD 2066
• CAS NO: 58237-09-5
• Molecular Weight: 209.288
• Mol File: 58237-09-5.mol

Chemical Properties

• CAS DataBase Reference: KWD 2066(CAS DataBase Reference)
• NIST Chemistry Reference: KWD 2066(58237-09-5)
• EPA Substance Registry System: KWD 2066(58237-09-5)

Safety Data

• Hazardous Substances Data: 58237-09-5(Hazardous Substances Data)

Upstream product

• 60853-18-1 2-tert-butylamino-1-(4-hydroxy-phenyl)-ethanone 
• 5324-15-2 4'-benzoyloxy-2-bromoacetophenone 
• 4254-67-5 2-bromo-1-(4-benzyloxyphenyl)-1-ethanone 
• 54696-05-8 4'-benzyloxy-acetophenone 
• 99-93-4 4-Hydroxyacetophenone 

Downstream Products

• 93739-47-0 VUF 8303 

Relevant articles and documents

Identification of Buctopamine and Mebuctopamine, a β2 Receptor Agonist and Its Metabolite, in Swine Hair and Feed Additives

4-[2-(t-Butylamino)-1-hydroxyethyl]phenol (buctopamine, 4), a new β2 receptor agonist (β2-agonist), was found to be an adulterant in feed additives for swine in Taiwan, where using β2-agonists in food-production animals is

BETA-HYDROXYETHYLAMINES FOR USE IN THE TREATMENT OR PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASES

There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of a non-alcoholic fatty liver disease (NAFLD), such as non-alcoholic steatohepatitis (NASH), wherein X, R1, R2, R3 and n have meanings as provided in the description.

COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA

There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of hyperglycaemia or a disorder characterized by hyperglycaemia, such as type 2 diabetes, wherein X, R1, R2, R3 and n have meanings as provided in the description.